We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+70.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$379M
AUM Growth
+$1.99M
(+0.53%)
Cap. Flow
-$143M
Cap. Flow
% of AUM
-37.85%
Top 10 Holdings %
Top 10 Hldgs %
49.33%
Holding
57
New
10
Increased
10
Reduced
18
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$7.92M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$7.56M |
| 3 |
TG Therapeutics
TGTX
|
+$6.44M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$5.32M |
| 5 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$5.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$18.8M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$13.9M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$11.7M |
| 4 |
Axsome Therapeutics
AXSM
|
+$8.85M |
| 5 |
ADVM
Adverum Biotechnologies
ADVM
|
+$7.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Wave Life Sciences
WVE
$1.12B
| $5.57M | 1.47% |
+535,000
| New | +$5.03M |
|
|
SURF
27
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $4.59M | 1.21% |
+700,000
| New | +$2.53M |
|
|
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.59M | 1.21% |
900,000
+71,541
| +9% | +$298K |
|
29
Fate Therapeutics
FATE
$324M
| $4.29M | 1.13% |
125,000
-100,000
| -44% | -$2.98M |
|
|
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
| $4.24M | 1.12% |
350,000
| – | – |
|
31
Aldeyra Therapeutics
ALDX
$102M
| $4.17M | 1.1% |
+1,000,000
| New | +$3.65M |
|
32
Xenon Pharmaceuticals
XENE
$6.6B
| $4.08M | 1.08% |
325,000
| – | – |
|
33
Arvinas
ARVN
$517M
| $4.03M | 1.06% |
120,000
+40,000
| +50% | +$1.7M |
|
34
Q32 Bio
QTTB
$255M
| $3.57M | 0.94% |
13,056
+1,945
| +18% | +$518K |
|
35
Cartesian Therapeutics
RNAC
$243M
| $2.84M | 0.75% |
33,333
-24,167
| -42% | -$2.19M |
|
36
Syndax Pharmaceuticals
SNDX
$2.02B
| $2.74M | 0.72% |
185,000
-65,000
| -26% | -$990K |
|
37
Gilead Sciences
GILD
$167B
| $1.92M | 0.51% |
+25,000
| New | +$1.92M |
|
38
PolyPid
PYPD
$103M
| $1.8M | 0.48% |
+3,333
| New | +$1.87M |
|
39
Altimmune
ALT
$558M
| $1.61M | 0.42% |
+150,000
| New | +$824K |
|
40
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $1.27M | 0.34% |
50,000
-62,695
| -56% | -$1.31M |
|
|
VRAY
41
DELISTED
ViewRay, Inc.
VRAY
| $672K | 0.18% |
300,000
-482,928
| -62% | -$1.03M |
|
42
Moderna
MRNA
$24.5B
| $642K | 0.17% |
+10,000
| New | +$548K |
|
43
Invesco CurrencyShares Euro Currency Trust
FXE
$354M
| $212K | 0.06% |
2,000
-18,830
| -90% | -$1.96M |
|
|
AMRN
44
CALL
Amarin Corp
AMRN
$292M
| – | – |
-8,280
| Closed | -$662K |
|
45
Biogen
BIIB
$30.4B
| – | – |
-3,250
| Closed | -$1.03M |
|
46
Coherus Oncology
CHRS
$216M
| – | – |
-150,000
| Closed | -$2.43M |
|
47
Cue Biopharma
CUE
$131M
| – | – |
-4,167
| Closed | -$1.77M |
|
48
Milestone Pharmaceuticals
MIST
$148M
| – | – |
-208,733
| Closed | -$384K |
|
49
Protagonist Therapeutics
PTGX
$9.06B
| – | – |
-227,827
| Closed | -$1.61M |
|
|
SAGE
50
DELISTED
Sage Therapeutics
SAGE
| – | – |
-65,000
| Closed | -$1.87M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Ghost Tree Capital held 57 positions worth $379M, up 0.53% from $377M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital withdrew a net $143M in Q2 2020, closing 14 positions and reducing 18 holdings. Its most notable exit was Verastem, an estimated $3.96M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 54% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in Acadia Pharmaceuticals worth $8M.
- Ghost Tree Capital's largest Q2 2020 buy was Acadia Pharmaceuticals: 165,000 shares worth $8M.
- Ghost Tree Capital added most to Iovance Biotherapeutics in Q2 2020, an estimated $7.56M increase.
- Ghost Tree Capital's biggest Q2 2020 reduction was Mersana Therapeutics, cutting an estimated $18.8M.
- Ghost Tree Capital fully exited Verastem in Q2 2020, selling an estimated $3.96M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $379M portfolio in Q2 2020.
- Ghost Tree Capital opened 10 new positions and closed 14 in Q2 2020.
- Ghost Tree Capital's portfolio value rose 0.53% quarter-over-quarter to $379M.
Based on Ghost Tree Capital's 13F filing for Q2 2020, filed 14 Aug 2020.